Brain Natriuretic Peptide for Prevention of Contrast-Induced Nephropathy After Percutaneous Coronary Intervention or Coronary Angiography

Xie, Yanling; Gao, Zhisong; Zu, Xiuguang; Li, Yongjun; Hao, Yuming; Chang, Liang

doi:10.1016/j.cjca.2014.08.012

Cited by 13 publications

(8 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the studies were judged to be at low risk of bias for 6 domains ( Fan et al, 2016a ; Xing et al, 2016 ; Zeng et al, 2019 ; Zhang et al, 2010 ; Zhang et al, 2020b ), according to the Cochrane Collaboration’s tool. 8 studies were judged to be at high risk of bias for they were not blinded ( Fan et al, 2019 ; Iranirad et al, 2017 ; Ko et al, 2013 ; Liu et al, 2014 ; Liu et al, 2016 ; Zhang et al, 2020a ; Nawa et al, 2015 ; Sun et al, 2015 ). One study was judged to be at high risk of bias for participants were randomized according to the participating centers and the severity of the renal dysfunction (estimated Glomerular Filtration Rate (eGFR) ≤40 or >40 mL/min) ( Ko et al, 2013 ).…”

Section: Resultsmentioning

confidence: 99%

Efficacy of brain natriuretic peptide vs. nicorandil in preventing contrast-induced nephropathy: a network meta-analysis

Mei

Luo

Chen

et al. 2022

PeerJ

View full text Add to dashboard Cite

This study aimed to conduct a network meta-analysis (NMA) to compare the efficacy of brain natriuretic peptide (BNP) vs nicorandil for preventing contrast-induced nephropathy (CIN). Databases of Pubmed, Cochrane, Embase, Web of Science were searched by keywords for eligible studies of randomized controlled trials investigating different agents (BNP, nicorandil, nitroglycerin, intravenous saline) for preventing CIN. The outcomes included a change in serum creatinine level at 48 h and the incidence of CIN after percutaneous coronary intervention (PCI) or coronary angiography (CAG). A total of 13 studies with 3,462 patients were included. Compared with intravenous saline alone, except for nitroglycerin (odds ratio [OR]: 1.02, 95% CI [0.36–2.88]), the other drugs significantly reduced the CIN incidence with OR of 0.35 (95% CI [0.24–0.51]) for BNP, 0.52 (0.29, 0.94) for usual-dose nicorandil, 0.28 (0.19, 0.43) for double-dose nicorandil. BNP and double-dose nicorandil significantly decreased the change of serum creatinine (SCr) levels with mean difference (MD) of −6.98, (−10.01, −3.95) for BNP, −8.78, (−11.63, −5.93) for double-dose nicorandil. No significant differences were observed in the change of SCr levels for nitroglycerin (−4.97, [−11.46, 1.52]) and usual-dose nicorandil (−2.32, [−5.52, 0.89]) compared with intravenous saline alone. For double-dose nicorandil, the CIN incidence and the change of SCr level in group of 4–5 days treatment course were more than group of less than or equal to 24 h treatment course (OR of 1.48, [0.63–3.46] and MD of 2.48, [−1.96, 6.91]). In conclusion, BNP and double-dose nicorandil can have effects on preventing the incidence of CIN and double-dose nicorandil performed better than BNP. In double-dose nicorandil groups, a course of less than or equal to 24 h before and after procedure performed with better efficacy than a course of 4–5 days.

show abstract

Section: Resultsmentioning

confidence: 99%

Efficacy of brain natriuretic peptide vs. nicorandil in preventing contrast-induced nephropathy: a network meta-analysis

Mei

Luo

Chen

et al. 2022

PeerJ

View full text Add to dashboard Cite

show abstract

“…Its effects include vasodilation, reduction of cardiac preload and afterload, inhibition of cardiac remodeling, renin-angiotensin-aldosterone system, sympathetic nervous system and release of adenosine and endothelin. BNP has also direct renal effects: it increases GFR and reduces sodium reabsorption in the proximal tubule and collecting duct, thus promoting diuresis [75]. A recent trial showed that the infusion of lyophilized recombinant human BNP for 24 h before coronary angiography or PCI reduced the incidence of CIN, as compared with isotonic saline (5.6% vs. 14.8%, p<0.01) [75].…”

Section: Other Interventionsmentioning

confidence: 99%

“…Prophylactic hemofiltration (in case of baseline severe renal impairment) [76] Drugs/interventions targeting alternative pathophysiologic mechanisms (recombinant B-type natriuretic peptide [75], ischemic preconditioning [78], phosphodiesterase type …”

Section: Accepted Manuscriptmentioning

confidence: 99%

Contrast-Induced Nephropathy: From Pathophysiology to Preventive Strategies

Azzalini

Spagnoli

2016

Canadian Journal of Cardiology

230

202

View full text Add to dashboard Cite

“…In anterior myocardial infarction complicated by cardiogenic shock, low-dose rhBNP can improve pulmonary capillary wedge pressure but does not increase drug-related severe adverse events[ 28 ]. Liu et al [ 29 ] reported that pre-treatment with rhBNP before coronary angiography or PCI could improve renal function and decrease CIN incidence. Due to their unique situation, more elderly AMI patients cannot receive hydration therapy, and the effectiveness of rhBNP in these patients after PCI was unclear.…”

Section: Discussionmentioning

confidence: 99%

Protective effect of recombinant human brain natriuretic peptide against contrast-induced nephropathy in elderly acute myocardial infarction patients: A randomized controlled trial

Zhang¹,

Li²,

Li³

2022

World J Clin Cases

View full text Add to dashboard Cite

BACKGROUND Increasing reports have demonstrated that recombinant human brain natriuretic peptide (rhBNP) can improve acute myocardial infarction (AMI) and heart failure. However, whether it can improve renal function and decrease the risk of contrast-induced nephropathy (CIN) in elderly AMI patients is still unclear. AIM To explore the effect of rhBNP on CIN in elderly AMI patients after percutaneous coronary intervention (PCI). METHODS One hundred and thirty-one elderly AMI patients underwent PCI from January 2017 to July 2021. Patients were either given 1 mL of 0.9% normal saline/(kg/h) for 72 h after PCI (control group, n = 66) and or intravenous rhBNP [1.5 mg/kg followed by 0.0075 mg/(kg/min)] for 72 h (rhBNP treatment group, n = 65). Serum creatinine and cystatin C levels, creatinine clearance rate, and eGFR were measured at 24 h, 48 h, and 72 h after PCI. Research nurses collected data on handwritten forms, and then stored them in password-protected electronic databases. RESULTS The creatinine clearance rate and eGFR were increased, while the creatinine and cystatin C levels were decreased significantly in the rhBNP treatment group compared to the control group at 48 h and 72 h. The incidence of CIN ( P = 0.028) and acute heart failure ( P = 0.017) also significantly decreased in the rhBNP group. No significant difference was noted between the two groups in cardiac death and recurrent AMI. CONCLUSION Early application of rhBNP could protect renal function and decrease the incidence of CIN after primary PCI and acute heart failure.

show abstract

Brain Natriuretic Peptide for Prevention of Contrast-Induced Nephropathy After Percutaneous Coronary Intervention or Coronary Angiography

Cited by 13 publications

References 39 publications

Efficacy of brain natriuretic peptide vs. nicorandil in preventing contrast-induced nephropathy: a network meta-analysis

Efficacy of brain natriuretic peptide vs. nicorandil in preventing contrast-induced nephropathy: a network meta-analysis

Contrast-Induced Nephropathy: From Pathophysiology to Preventive Strategies

Protective effect of recombinant human brain natriuretic peptide against contrast-induced nephropathy in elderly acute myocardial infarction patients: A randomized controlled trial

Contact Info

Product

Resources

About